Evidence map›Paper›PMID 40723912›Full record

ReviewBiomolecules2025

Synergizing Liquid Biopsy and Hybrid PET Imaging for Prognostic Assessment in Prostate Cancer: A Focus Review.

Federica Stracuzzi, Sara Dall' Armellina, Gayane Aghakhanyan, Salvatore C Fanni, Giacomo Aringhieri, Lorenzo Faggioni, Emanuele Neri, Duccio Volterrani, Dania Cioni

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Federica StracuzziNuclear Medicine Unit, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione (ARNAS) Garibaldi, 95124 Catania, Italy.
Sara Dall' ArmellinaNuclear Medicine Unit, Service Area Department, Azienda Socio-Sanitaria Territoriale (ASST)-Rhodense P.O. Bollate, 994301 Milan, Italy.ORCID 0000-0001-9504-7626
Gayane AghakhanyanNuclear Medicine Unit, Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0001-5152-497X
Salvatore C FanniAcademic Radiology, Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-4003-3320
Giacomo AringhieriAcademic Radiology, Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0003-0842-5372
Lorenzo FaggioniAcademic Radiology, Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0001-5262-4489
Emanuele NeriAcademic Radiology, Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0001-7950-4559
Duccio VolterraniNuclear Medicine Unit, Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, 56126 Pisa, Italy.
Dania CioniAcademic Radiology, Department of Surgical, Medical, Molecular Pathology and Emergency Medicine, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-5120-886X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Positron emission tomography (PET) and liquid biopsy have independently transformed prostate cancer management. This review explores the complementary roles of PET imaging and liquid biopsy in prostate cancer, focusing on their combined diagnostic, monitoring, and prognostic potential. A systematic search of PubMed, Scopus, and Cochrane Library databases was conducted to identify human studies published in English up to January 2025. Seventeen studies met the inclusion criteria and were analyzed according to PRISMA guidelines. Across the included studies, PET-derived imaging metrics, such as metabolic activity and radiotracer uptake, correlated consistently with liquid biopsy biomarkers, including circulating tumor cells and cell-free DNA. Their joint application demonstrated added value in early detection, treatment monitoring, and outcome prediction, particularly in castration-resistant prostate cancer. Independent and synergistic prognostic value was noted for both modalities, including survival outcomes such as overall survival and progression-free survival. Combining PET imaging and liquid biopsy emerges as a promising, non-invasive strategy for improving prostate cancer diagnosis, monitoring, and therapeutic stratification. While preliminary findings are encouraging, large-scale prospective studies are essential to validate their integrated clinical utility.

Indexed as

Positron-Emission TomographyProstatic NeoplasmsBiomarkers, TumorHumansLiquid BiopsyMaleNeoplastic Cells, CirculatingPrognosisBiomarkers, Tumorcancer biomarkerscell free DNAcirculating tumor cellsimaging biomarkersliquid biopsyPET/CTPET/MRprecision medicineprostate cancertranslational oncology

Identifiers

PMID40723912
PMCPMC12292956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.